2023 Specialty Day All-Access Pass-Biologics for Chronic Tendinopathy

Video Transcription

Video Summary

In a video, Jason Jagoo from the University of Colorado discusses tendinopathy. Through analyzing normal and pathologic tendons at a cellular level, they found that tendinopathy cells cannot synthesize the matrix necessary for tendon regeneration. These cells also have lost their ability to react to their environment and produce an inflammatory matrix. Tendinopathy is now believed to be a genetic alteration in affected cells that prevents tendon production. Current biologic therapies such as PRP have limited effectiveness, but bone marrow aspirate appears promising in restoring cell production. Surgery may be necessary in some cases, and specific techniques like tendon scraping and fenestration can provide additional relief. Overall, future dosing of biologics and bone marrow cells may yield better results in treating tendinopathy.

Asset Caption

Jason L. Dragoo, M.D., FAANA

Keywords

tendinopathy

cellular level

tendon regeneration

genetic alteration

biologic therapies